测试分析报告范例结直肠癌肝转移

导的方法，平均有效率仅20%，意味着80%的患者在第一次用药前就注定治疗无效的最终结果，远远现代医学研究大大促进了肿瘤治疗，随着以肿瘤组学为基础的精准医疗的蓬勃发展，针对每个患“量体裁衣”的效果。通过临床手术样本，针对肿瘤组进序，获得组信息，通过现物信息学分析，揭示有效变异；在此基础上，通过分析FDA批准的靶向药物的作用靶点和患者具体的突变之间的关系为有特定突变的患者寻找针对性的靶向治疗方式，从而鉴定得到患者特定的药效图谱，指导医生依据化的测试分析而最终给患者用药。肿瘤类型：结直肠癌肝转移报告日期：20XX-XXPAGE10 第13572 FDA无（FDA批准，CFDA未批准无无PIK3C2B编码的蛋白属于PI3K蛋白，在细胞增殖，迁移和凋亡等过程中起到重要的调节作用10PIK3C2B12,17–合治疗后，有5例获得部分缓解18。 GuidelinesFDA批准BRAF抑制剂威罗和达拉、MEK抑制剂曲美替尼用于治疗BRAFV600突变阳性的黑色素瘤21-23FDA批准EGFR抑制剂替尼、厄洛替尼、阿法替尼用于治疗EGFR突变的非小细胞肺癌24-26FDA批准EGFR抑制剂替尼、厄洛替尼、阿法替尼用于KRAS野生型非小细胞肺癌；EGFR单抗帕尼和西妥昔用于KRAS野生型结肠癌27性的28-30意义不明的变异 注释:该患者样本中检测出了多个意义不明的变异，这些变异在科研文献中还未被充分阐明。我们选取在将来可能具有临床意义 该产品被设计用于检测实体肿瘤中的以下信息，a.已确认的与靶向药物治疗相关的变异，包括已批准的和处于临床试验药物；b.现有知识体系已明确的驱动肿瘤发生的变异。现有检测包括365个和25个融合。该检测产品会定期地随着肿瘤相关知C 碱基替换频率 Hynes,N.E.&Lane,H.A.ERBBreceptorsandcancer:thecomplexityoftargetedinhibitors.Naturereviews.Cancer5,341-354Moasser,M.M.TheoncogeneHER2:itssignalingandtransformingfunctionsanditsroleinhumancancerpathogenesis.Oncogene26,6469-6487(2007).Miller,T.W.,Rexer,B.N.,Garrett,J.T.&Arteaga,C.L.Mutationsinthephosphatidylinositol3-kinasepathway:roleintumorprogressionandtherapeuticimplicationsinbreastcancer.Breastcancerresearch:BCR13,224(2011).Hurvitz,S.A.,Hu,Y.,O'Brien,N.&Finn,R.S.CurrentapproachesandfuturedirectionsinthetreatmentofHER2-positivebreastCancertreatmentreviews39,219-229Higgins,M.J.&Baselga,J.Targetedtherapiesforbreastcancer.TheJournalofclinicalinvestigation121,3797-3803Bose,R.etal.ActivatingHER2mutationsinHER2geneamplificationnegativebreastcancer.Cancerdiscovery3,224-237Greulich,H.etal.Functional ysisofreceptortyrosinekinasemutationsinlungcanceridentifiesoncogenicextracellularmutationsofERBB2.ProceedingsoftheNationalAcademyofSciencesoftheUnitedStatesofAmerica109,14476-14481(2012).Vogel,C.L.etal.Efficacyandsafetyoftrastuzumabasasingleagentinfirst-linetreatmentofHER2-overexpressingmetastaticbreastcancer.Journalofclinicaloncology:officialjournaloftheAmericanSocietyofClinicalOncology20,719-726(2002).Nahta,R.&Esteva,F.J.HER2therapy:molecularmechanismsof .Breastcancerresearch:BCR8,215Falasca,M.&Maffucci,T.RoleofclassIIphosphoinositide3-kinaseincellsignalling.BiochemicalSocietytransactions35,211-214Nobusawa,S.etal.Intratumoralpatternsofgenomicimbalanceinglioblastomas.Brainpathology20,936-944Liu,Z.,Sun,C.,Zhang,Y.,Ji,Z.&Yang,G.Phosphatidylinositol3-kinase-C2betainhibitscistin-mediatedapoptosisviatheAktpathwayinoesophagealsquamouscellcarcinoma.TheJournalofinternationalmedicalresearch39,1319-1332(2011).Boller,D.etal.TargetingPI3KC2betaimpairsproliferationandsurvivalinacuteleukemia,braintumoursandneuroendocrineAnticancerresearch32,3015-3027Gu,L.,Feng,J.,Xu,H.,Luo,M.&Su,D.PolyphyllinIinhibitsproliferationandmetastasisofovariancancercelllineHO-8910PMinvitro.Journaloftraditional medicine=Chungitsachihyingwenpan/sponsoredbyAll- AssociationofTraditionalMedicine,Academyof Medicine33,325-333Zhang,L.etal.Integrativegenomic ysisofphosphatidylinositol3'-kinasefamilyidentifiesPIK3R3asapotentialtherapeutictargetinepithelialovariancancer.Clinicalcancerresearch:anofficialjournaloftheAmericanAssociationforCancerResearch13,5314-5321Russo,A.,Okur,M.N.,Bosland,M.&O'Bryan,J.P.Phosphatidylinositol3-kinase,class2beta(PI3KC2beta)isoformcontributestoneuroblastomatumorigenesis.Cancerletters359,262-268(2015).Low,S.etal.Pathogeneticpathwaysleadingtoglioblastomamultiforme:associationbetweengeneexpressions toAnticancerresearch28,3729-3732Ramanathan,R.K.etal.LowoverexpressionofHER-2/neuinadvancedcolorectalcancerlimitstheusefulnessoftrastuzumab(Herceptin)andirinotecanastherapy.AphaseIItrial.Cancerinvestigation22,858-865(2004).Kwak,E.L.etal.Anasticlymphomakinaseinhibitioninnon-small-celllungcancer.TheNewEnglandjournalofmedicine363,1693-1703(2010).Shaw,A.T.etal.Clinicalfeaturesand eofpatientswithnon-small-celllungcancerwhoharborEML4-ALK.Journalofclinicaloncology:officialjournaloftheAmericanSocietyofClinicalOncology27,4247-4253(2009).Sosman,J.A.etal.SurvivalinBRAFV600-mutantadvancedmelanomatreatedwithvemurafenib.TheNewEnglandjournalof366,707-714Hauschild,A.etal.DabrafenibinBRAF-mutatedmetastaticmelanoma:amulticentre,open-label,phase3randomisedcontrolledLancet380,358-365Flaherty,K.T.etal.CombinedBRAFandMEKinhibitioninmelanomawithBRAFV600mutations.TheNewEnglandjournalofmedicine367,1694-1703(2012).Cappuzzo,F.etal.Clinicalexperiencewithgefitinib:anupdate.Criticalreviewsinoncology/hematology58,31-45Paez,J.G.etal.EGFRmutationsinlungcancer:correlationwithclinicalresponsetogefitinibtherapy.Science304,1497-1500Yasuda,H.,Kobayashi,S.&Costa,D.B.EGFRexon20insertionmutationsinnon-small-celllungcancer:preclinicaldataandclinicalimplications.TheLancet.Oncology13,e23-31(2012).Shigematsu,H.&Gazdar,A.F.Somaticmutationsofepidermalgrowthfactorreceptorsignalingpathwayinlungcancers.Internationaljournalofcancer.Journalinternationalducancer118,257-262(2006).Romond,E.H.etal.TrastuzumabplusadjuvantchemotherapyforoperableHER2-positivebreastcancer.TheNewEnglandjournalofmedicine353,1673-1684(2005).Schneeweiss,A.etal.Pertuzumabplustrastuzumabincombinationwithstandardneoadjuvantanthracycline-containingandanthracycline-chemotherapyregimensinpatientswithHER2-positiveearlybreast